What the SURMOUNT-1 tirzepatide weight loss results mean in practice

The decision most people are actually making when they look up these results

When someone searches for the SURMOUNT-1 results, the real question underneath is usually a personal one: is this treatment likely to work for me, and is that kind of weight loss realistic? That is a fair question and it deserves a careful answer, not just a headline percentage.

Trials report group averages. SURMOUNT-1's 20–21% figure at 15mg represents the mean across everyone in that arm of the study, a spread of real people, some of whom lost more, some less. A person's starting weight, metabolic health, how well they tolerate dose titration, their diet and activity alongside treatment, and how consistently they take each dose all pull the final result in different directions. There is no formula that converts a trial average into an individual guarantee.

There is a common misconception that higher doses automatically produce proportionally higher losses in every individual. The trial data show the dose-response relationship holds at a population level, but individual responses vary considerably. Some people see their best results at 10mg; others need 15mg; a small number find even lower doses produce meaningful change. A prescriber follows that through with you over time, which is why clinical oversight matters throughout treatment, not only at the start. For a more detailed breakdown of what realistic timelines look like, the tirzepatide weight loss results overview on our site walks through these patterns by dose and duration.

What SURMOUNT-1 measured and why the study design matters

SURMOUNT-1 enrolled 2,539 adults across multiple countries, randomised them to tirzepatide 5mg, 10mg, or 15mg, or placebo, and followed them for 72 weeks, roughly 17 months. All participants received structured lifestyle support throughout. The primary endpoint was percentage weight change at 72 weeks; secondary endpoints included the proportion achieving at least 5%, 10%, 15% and 20% weight loss.

At 15mg, around 57% of participants lost at least 20% of their body weight, a figure that had rarely been seen outside surgical studies. At 5mg, around a third of participants hit that same 20% threshold. The placebo group, receiving the same lifestyle support, averaged roughly 3% loss, which clarifies how much of the result is attributable to the medicine itself rather than the programme around it.

The study excluded people with type 2 diabetes (separately studied in SURMOUNT-2), recent cardiovascular events, and certain other conditions. That matters when reading the results: the population studied does not include everyone who might be considered for treatment. NICE's appraisal of tirzepatide, published in December 2024, reviewed SURMOUNT-1 alongside other evidence and concluded the medicine represents a clinically meaningful option for eligible adults, you can read the full assessment at NICE technology appraisal TA1026.

If you are curious about what the earliest weeks of the data looked like, our page on four-week tirzepatide results covers that period specifically.

The factors that most influence where you land relative to the trial average

Starting BMI plays a role, but perhaps not in the way many people expect. Participants with higher starting weights tend to lose a larger absolute amount of weight while the percentage figure can be similar or slightly lower. What consistently matters more across the data is adherence: people who reached and stayed on their maintenance dose, took each injection on schedule, and combined treatment with genuine changes to eating and activity achieved the outcomes closest to the top-line trial figures.

Dose titration is the other key variable. Tirzepatide starts at 2.5mg, a dose chosen to let your body adjust rather than to produce rapid weight loss from week one. The schedule moves upward roughly every four weeks, guided by your prescriber. Jumping ahead or staying at a sub-therapeutic dose for too long both affect results. That titration conversation is also where questions like how you are tolerating side effects and whether your progress is on track get properly addressed.

For people who want a sense of what three months into treatment looks like compared to longer-term data, the three-month results page sets those early numbers alongside the 72-week picture. The page on how long Mounjaro takes to work is also useful if you are trying to set realistic expectations for the first few weeks.

What these results mean if you are considering treatment

The SURMOUNT-1 data are genuinely striking for a non-surgical intervention, and it is reasonable to find them encouraging. They do not, though, predict your individual outcome, and the trial's lifestyle-support conditions remind us that the medicine works best as part of a broader approach, not as a standalone fix.

Whether tirzepatide is the right option for you depends on your medical history, current medications, BMI, any weight-related conditions, and other factors a prescriber needs to assess. The weight loss on tirzepatide guide covers how the medicine fits into a longer-term plan, and the Mounjaro overview explains the UK licensing picture and what the consultation process involves.

For cost context, if that is part of your thinking, the Mounjaro pricing guide explains what private treatment typically includes and how to read the figures honestly. And if you have already looked at before-and-after accounts online and are trying to calibrate them against the trial evidence, the before-and-after results page places those stories in the context of what the clinical data actually show.

When you are ready to find out whether treatment is appropriate for you, our prescribers (not an algorithm) review every consultation personally. Speak to our prescribers through a free consultation; it costs nothing and commits you to nothing.